Search Page

1

Cite

Share

Impact of routine clinic measurement of serum C-peptide in people with a clinician-diagnosis of type 1 diabetes.

Foteinopoulou E, Clarke CAL, Pattenden RJ, Ritchie SA, McMurray EM, Reynolds RM, Arunagirinathan G, Gibb FW, McKnight JA, Strachan MWJ. Foteinopoulou E, et al. Among authors: pattenden rj. Diabet Med. 2021 Jul;38(7):e14449. doi: 10.1111/dme.14449. Epub 2020 Nov 22. Diabet Med. 2021. PMID: 33131101

Cite

Share

2

Cite

Share

Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.

Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones GR, Lees CW. Plevris N, et al. Among authors: pattenden rj. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1835-1844.e6. doi: 10.1016/j.cgh.2020.08.022. Epub 2020 Aug 13. Clin Gastroenterol Hepatol. 2021. PMID: 32798706

Cite

Share

3

Cite

Share

Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease.

Plevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden RJ, Arnott ID, Jones GR, Lees CW. Plevris N, et al. Among authors: pattenden rj. Frontline Gastroenterol. 2019 Jul 3;11(2):117-123. doi: 10.1136/flgastro-2019-101197. eCollection 2020 Mar. Frontline Gastroenterol. 2019. PMID: 32133110 Free PMC article.

Cite

Share

4

Cite

Share

Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes.

Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW. Plevris N, et al. Among authors: pattenden rj. Dig Dis Sci. 2019 Jun;64(6):1660-1667. doi: 10.1007/s10620-018-5406-8. Epub 2018 Dec 7. Dig Dis Sci. 2019. PMID: 30535885

Cite

Share

5

Cite

Share

Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.

Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Plevris N, et al. Among authors: pattenden rj. Inflamm Bowel Dis. 2019 May 4;25(6):1036-1043. doi: 10.1093/ibd/izy320. Inflamm Bowel Dis. 2019. PMID: 30335139 Clinical Trial.

Cite

Share

6

Cite

Share

Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.

Kalla R, Kennedy NA, Ventham NT, Boyapati RK, Adams AT, Nimmo ER, Visconti MR, Drummond H, Ho GT, Pattenden RJ, Wilson DC, Satsangi J. Kalla R, et al. Among authors: pattenden rj. Am J Gastroenterol. 2016 Dec;111(12):1796-1805. doi: 10.1038/ajg.2016.342. Epub 2016 Sep 6. Am J Gastroenterol. 2016. PMID: 27596694

Cite

Share

7

Cite

Share

Crystallization of the oligopeptide-binding protein AppA from Bacillus subtilis.

Wright L, Blagova E, Levdikov VM, Brannigan JA, Pattenden RJ, Chambers J, Wilkinson AJ. Wright L, et al. Among authors: pattenden rj. Acta Crystallogr D Biol Crystallogr. 2004 Jan;60(Pt 1):175-7. doi: 10.1107/s0907444903025320. Epub 2003 Dec 18. Acta Crystallogr D Biol Crystallogr. 2004. PMID: 14684921

Cite

Share

8

Cite

Share

Serum free light chains; the need to establish local reference intervals.

Pattenden RJ, Rogers SY, Wenham PR. Pattenden RJ, et al. Ann Clin Biochem. 2007 Nov;44(Pt 6):512-5. doi: 10.1258/000456307782268200. Ann Clin Biochem. 2007. PMID: 17961304

Cite

Share

9

Cite

Share

The value of serum free light chains in a case of Waldenstrom's macroglobulinaemia that produces a type I cryoglobulinaemia.

Pattenden RJ, Davidson KL, Wenham PR. Pattenden RJ, et al. Ann Clin Biochem. 2009 Nov;46(Pt 6):531-2. doi: 10.1258/acb.2009.009056. Epub 2009 Oct 12. Ann Clin Biochem. 2009. PMID: 19822697

Cite

Share